baha the information company

baha is a leading provider of real-time market data, financial news, technology and solutions for the financial industry. baha offers real-time data terminals for professionals, global financial market data covering over 12 million financial instruments on more than 150 exchanges, as well as 24/7 breaking news with global coverage and free web and mobile apps. From a total of around 200 real-time data providers worldwide, only Reuters 1851, Bloomberg 1981 and now baha in 2021 were named after the founder.

Werewolf Therapeutics/ US95075A1079 /

2024-08-01 5:06:52 PM	Chg. +0.09	Volume	Bid5:30:17 PM	Ask5:30:17 PM	High	Low
2.34USD	+4.00%	1,132 Turnover: 2,618.10	2.27Bid Size: 100	2.34Ask Size: 200	2.42	2.26

GlobeNewswire 06-25 Werewolf Therapeutics Highlights Initial Safety and Efficacy Data from its Ongoing Phase 1 Clinical ...

GlobeNewswire 06-01 Werewolf Therapeutics to Present Data from Ongoing Phase 1/1b Clinical Trial of WTX-124 as Monothera...

GlobeNewswire 05-30 Werewolf Therapeutics to Participate at the Jefferies Global Healthcare Conference

GlobeNewswire 05-23 Werewolf Therapeutics to Present Updated Data from Phase 1/1b Clinical Trial of WTX-124 as Monothera...

GlobeNewswire 05-03 Werewolf Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

GlobeNewswire 04-24 Werewolf Therapeutics Announces WTX-124 Clinical Abstract Accepted for Presentation at the 2024 Amer...

GlobeNewswire 04-23 Werewolf Therapeutics Presents First Preclinical Data Highlighting IL-10 INDUKINE Molecules as a Pot...

GlobeNewswire 04-05 Werewolf Therapeutics Presents Preclinical Results Demonstrating Anti-Tumor Effects of Pro-Inflammat...

GlobeNewswire 04-04 Werewolf Therapeutics to Present First-of-Its-Kind Data Demonstrating Utility for PREDATOR™ Platform...

GlobeNewswire 03-07 Werewolf Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Busin...

GlobeNewswire 03-06 Werewolf Therapeutics to Present at the 2024 Leerink Partners Global Biopharma Conference

GlobeNewswire 03-05 Werewolf Therapeutics Announces Upcoming Presentations at AACR Annual Meeting 2024

GlobeNewswire 01-08 Werewolf Therapeutics Provides Business Update and Highlights 2024 Strategic Outlook

GlobeNewswire 01-04 Werewolf Therapeutics Appoints Michael Atkins, M.D., to its Board of Directors

GlobeNewswire 2023-11-22 Werewolf Therapeutics to Present at the Evercore ISI HealthCONx Conference

GlobeNewswire 2023-11-14 Werewolf Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update

GlobeNewswire 2023-11-03 Werewolf Therapeutics Presents Preliminary Monotherapy Data from Phase 1/1b Clinical Trial Establish...

GlobeNewswire 2023-10-31 Werewolf Therapeutics to Present Clinical and Preclinical Data at the Society for Immunotherapy of C...

GlobeNewswire 2023-09-27 Werewolf Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer’s ...

GlobeNewswire 2023-09-11 Werewolf Therapeutics to Host KOL Event Highlighting IL-2 Landscape and Opportunity for WTX-124

GlobeNewswire 2023-09-05 Werewolf Therapeutics to Participate in Upcoming Investor Conferences

GlobeNewswire 2022-03-24 Werewolf Therapeutics Reports Fourth Quarter 2021 and Full Year 2021 Financial Results and Provides ...

GlobeNewswire 2022-03-16 Werewolf Therapeutics Announces Publication of Data Demonstrating the Preclinical Efficacy of WTX-12...

GlobeNewswire 2022-03-15 Werewolf Therapeutics Announces Upcoming Presentations at AACR 2022 Annual Meeting

GlobeNewswire 2022-02-08 Werewolf Therapeutics to Present at the SVB Leerink Global Healthcare Conference

Werewolf Therapeutics/ US95075A1079 /

If you wish to receive reply to your feedback, please provide your email address.